name of work: e-tender for procurement of drug items - abacavir 300mg tab., "act combi-blister pack tablet (for 1-4 year) specification: each combi blister pack containing 3 tablets of artesunate (each tablet of artesunate 50mg strength) and 1 tablet of sulphadoxine pyremethamin (500mg + 25mg) each row, no of tablet: o 1st row (day-1) : one tablet of artesunate (50 mg) and one tablet of sulphadoxine pyremethamin (500mg + 25mg) o 2nd row (day-2) : one tablet of artesunate (50 mg) o 3rd row (

Health And Family Welfare Department has invited bids for the name of work: e-tender for procurement of drug items - abacavir 300mg tab., "act combi-blister pack tablet (for 1-4 year) specification: each combi blister pack containing 3 tablets of artesunate (each tablet of artesunate 50mg strength) and 1 tablet of sulphadoxine pyremethamin (500mg + 25mg) each row, no of tablet: o 1st row (day-1) : one tablet of artesunate (50 mg) and one tablet of sulphadoxine pyremethamin (500mg + 25mg) o 2nd row (day-2) : one tablet of artesunate (50 mg) o 3rd row (day-3) : one tablet of, artesunate (50 mg) self life of the act combi-blister pack: 2 years. colour : yellow", "act combi-blister pack tablet (for adults i.e. 15 years & above) specification: each combi blister pack containing 3 tablets of artesunate (each tablet of artesunate 200mg strength) and 2 tablet of sulphadoxine pyremethamin (750mg, + 37.5mg) or 3 tablet of sulphadoxine pyremethamin (500mg, + 25mg) each row no of tablet: o 1st row day-1 : one tablet of artesunate (200 mg) and two tablet of sulphadoxine pyremethamin (750mg + 37.5mg) or 3 tablet of sulphadoxine pyremethamin (500mg + 25mg) o 2nd row day-2 : one tablet of artesunate (200 mg) o 3rd row day-3 : one tablet of, artesunate (200 mg) self life of the act combi-blister pack: 2 years. colour : white", amikacin inj. i.p. 100 mg/2ml.vial, amino acid injection (not less than 10 %), anti - thymocyte globulin 250 mg inj., anti d gamma globulin inj. 300 mcg in vial / prefilled syringe i.p., bisoprolol fumerate tab (2.5mg), botulinum toxin type - a 100 units vial, capd solution 1.5% in 2 ltrs, chlorpromazine hcl injection i.p. 50mg /2ml.ampoules, clotrimazole powder 1% w/w, cytosine arabinoside inj. (powder) 1g./ vial, dicyclomine drops 10mg./ml., diphtheria antitoxin inj.i.p. 10,000 i.u./vial in 10ml vial, erythropoietin inj. ip 2000 iu, ethambutol hcl tabs. i.p. 800 mg., fluconazole dispersible tab 50 mg, flurourocil inj. i.p. 500mg. in 10ml. amp., gancyclovir inj. 500mg/vial, human hepatitis b immunoglobulin (im) inj. 100 iu/ml, human normal immunoglobulin-igm enriched in 10 ml vial / amp., itraconazole 100 mg cap., ketorolac tromethamine 0.4% w/v ophthalmic solution, levosalbutamol 50 mcg + ipratropium bromide 20 mcg / puff, lopinavir 100 mg + ritonavir 25 mg tab., lopinavir 200 mg + ritonavir 50 mg tab., mefenamic acid 500 mg cap., memantine 5mg tab., merbromin solution usnf (mercurochrome solution 2% w/v), metformin tab 1000 mg (sr/pr/er), mitomycin c inj. 10mg /vial, morphine sulphate b.p. 30 mg tab. (sr), multivitamin oral drop with zinc ip: each 1 ml. contains : vitamin a concentrate 2500iu, vit d3 (chlorocalciferol ) 200iu, thiamine hcl 0.5mg, riboflavin ip 0.5mg (as riboflavin sodium phosphate), pyridoxine hcl 0.5mg, d-panthanol 1.5mg, nicotinamide 5mg, ascorbic acid 25mg, vitamin e acetate 2.5 iu, zinc sulphate 11mg (eqv. to elemental zinc 2.5mg), "recombinant human coagulation factor vii inj. (rfvila) 2mg, / 1mg", recombinant human interferon beta 1a 44mcg pfs/vial, risperidone 25mg inj. (2ml vial), risperidone 37.5mg inj. (2ml vial), sevelamer hydrocloride tab 400mg, spironolactone tab ip 50 mg, succinylcholine chloride inj. 50mg./ml., tenecteplase 40mg inj, tetanus toxiod (absorbed) inj.i.p. 5.0 ml. vial for 10 doses., tocilizumab inj. 200 mg/vial, tolperisone 150mg tab., total parenteral nutrition (lipid emulsion + amino acid solution + glucose solution) - total 1000 ml 3 - chamber bag ( total solution 1000ml to 3000ml), zidovudine 300 mg+ lamivudine 150mg tabs under table-a, for two years from the date of a., with an EMD of ₹0.02 Cr. Please refer to the tender document for project value details. Interested bidders can submit applications until 27 October 2026, with the technical opening scheduled for 27 October 2026.